Nubriveo (Brivaracetam)

Brivaracetam, the active ingredient in Nubriveo, is an anticonvulsant (racetam) presented as an oral tablet for oral use. It is used as adjunctive therapy for focal (partial) onset seizures in patients with epilepsy and is prescribed by neurologists as part of comprehensive seizure management.

GNH USA supplies Nubriveo as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. Our distribution network ensures reliable delivery and regulatory compliance across EU and global markets. We maintain stringent quality controls and provide technical support to healthcare providers.

Brivaracetam is an anticonvulsant that acts on seizure activity in the central nervous system.

- Focal (partial) onset seizures: Reduces seizure frequency as adjunctive therapy in patients with epilepsy. - Refractory focal seizures: Provides additional seizure control when other antiepileptic drugs are insufficient. - Epilepsy with focal onset: Improves overall seizure management as part of a comprehensive treatment plan.

Brivaracetam may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Dizziness - Somnolence - Fatigue - Headache - Nausea - Irritability

Serious or Rare Side Effects: - Depression - Suicidal thoughts or behavior - Severe allergic reaction (anaphylaxis) - Rash with systemic involvement - Blood dyscrasias - Elevated liver enzymes

When prescribing Brivaracetam, clinicians should consider several safety measures.

- Renal impairment: Adjust dose in patients with moderate to severe renal dysfunction. - Hepatic impairment: Use caution and monitor liver function in patients with hepatic disease. - Depression: Monitor for new or worsening depressive symptoms or suicidal ideation. - Concomitant CNS depressants: Avoid excessive sedation when combined with other CNS depressants. - Pregnancy: Limited data; weigh potential benefits against risks before use in pregnant women. - Store at room temperature: Keep in original packaging, protect from moisture and light.

Brivaracetam can interact with other medicines, affecting its plasma levels or enhancing central nervous system effects.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): May increase brivaracetam concentrations, risking toxicity. - Other CNS depressants (e.g., benzodiazepines, opioids): May exacerbate sedation and respiratory depression.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., carbamazepine, phenytoin, oxcarbazepine): May reduce brivaracetam levels, decreasing efficacy. - Alcohol: Can potentiate central nervous system depression. - Antidepressants (e.g., SSRIs): May increase risk of mood changes; monitor patient.